Landiolol in patients with septic shock

Affiliations

¹ Department of Critical Care, School of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Thessaly, Greece.
² Department of Critical Care, School of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Thessaly, Greece. mantzk@outlook.com.

Vassilios Vazgiourakis et al. Intensive Care Med. 2025 Jan.

. 2025 Jan;51(1):221.

doi: 10.1007/s00134-024-07706-y. Epub 2024 Nov 11.

¹ Department of Critical Care, School of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Thessaly, Greece.
² Department of Critical Care, School of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Thessaly, Greece. mantzk@outlook.com.

No abstract available

Conflict of interest statement

Declarations. Conflict of interest: ICMJE disclosure forms were provided for every author.

1. Rehberg S, Frank S, Černý V et al (2024) Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. https://doi.org/10.1007/s00134-024-07587-1 - DOI - PubMed - PMC
1. Kakihana Y, Nishida O, Taniguchi T et al (2020) Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8:863–872 - DOI - PubMed
1. Whitehouse T, Hossain A, Perkins GD (2023) Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. JAMA 330:1641–1652 - DOI - PubMed - PMC
1. Morelli A, Romano SM, Sanfilippo F et al (2020) Systolic-dicrotic notch pressure difference can identify tachycardic patients with septic shock at risk of cardiovascular decompensation following pharmacological heart rate reduction. Br J Anaesth 125:1018–1024 - DOI - PubMed